Everolimus BSA Conjugate Solution

<strong>Everolimus BSA Conjugate </strong>_x000D_ <table width="643">_x000D_ <tbody>_x000D_ <tr>_x000D_ <td>Catalog number:</td>_x000D_ <td>P2010024</td>_x000D_ </tr>_x000D_ <tr>_x000D_ <td>Lot number:</td>_x000D_ <td>Batch Dependent</td>_x000D_ </tr>_x000D_ <tr>_x000D_ <td>Expiration date:</td>_x000D_ <td>Batch Dependent</td>_x000D_ </tr>_x000D_ <tr>_x000D_ <td>Purity:</td>_x000D_ <td>&gt; 95%</td>_x000D_ </tr>_x000D_ <tr>_x000D_ <td>Concentration:</td>_x000D_ <td>1 mg/mL</td>_x000D_ </tr>_x000D_ <tr>_x000D_ <td>Package Size:</td>_x000D_ <td>0.5 mg</td>_x000D_ </tr>_x000D_ <tr>_x000D_ <td>Molecular Weight:</td>_x000D_ <td>71 kDa (average)</td>_x000D_ </tr>_x000D_ <tr>_x000D_ <td>Storage:</td>_x000D_ <td>-20°C. Avoid repeated freeze/thaw cycles.</td>_x000D_ </tr>_x000D_ <tr>_x000D_ <td>Other names:</td>_x000D_ <td>BSA-Everolimus, Everolimus-BSA, BSA conjugated to Everolimus, 40-O-(2-hydroxyethyl)-sirolimus BSA, Everolimus Bovine Serum Albumin Conjugate, Everolimus [BSA].</td>_x000D_ </tr>_x000D_ <tr>_x000D_ <td>Keywords:</td>_x000D_ <td>BSA conjugate, Everolimus, Certican, Zortress, Afinitor, Votubia, Evertor.</td>_x000D_ </tr>_x000D_ <tr>_x000D_ <td>Buffer:</td>_x000D_ <td>1X Phosphate Buffer Saline, pH 7.4.</td>_x000D_ </tr>_x000D_ </tbody>_x000D_ </table>_x000D_ <strong>About Everolimus</strong>_x000D_ _x000D_ Everolimus is a synthetic derivative of the natural compound sirolimus (40-O-(2-hydroxyethyl)-sirolimus). Everolimus has both immunosuppressant and anti-angiogenic properties. As a result, this molecule finds several applications in organ transplant as well as chemotherapy. Inside the cell, Everolimus inhibits the activation of the mammalian target of <a href="https://pubmed.ncbi.nlm.nih.gov/27208895/">Rapamycin</a> (sirolimus) (mTOR)._x000D_ _x000D_ <a href="https://moleculardepot.com/wp-content/uploads/2021/09/MKT-008-Tacrolimus-Brochure.pdf"><strong>Complete Tacrolimus Product Line</strong></a>_x000D_ _x000D_ <a href="https://moleculardepot.com/wp-content/uploads/2021/09/MKT-008-Tacrolimus-Brochure.pdf">Download Brochure</a>_x000D_ _x000D_ <a href="https://moleculardepot.com/wp-content/uploads/2021/09/MKT-008-Tacrolimus-Brochure.pdf"><img class="media-library__list-item-centered is-image" draggable="false" src="https://i0.wp.com/moleculardepot.com/wp-content/uploads/2019/02/cropped-LogoHD-3.png?ssl=1&amp;resize=438,438" alt="cropped-LogoHD-3.png" width="94" height="94" /></a>_x000D_ _x000D_ <strong>References</strong>_x000D_ <ul>_x000D_ <li class="auths">Montero N, Pascual J. Immunosuppression and Post-transplant Hyperglycemia. <span role="menubar">Curr Diabetes Rev.</span> 2015;11(3):144-54.</li>_x000D_ <li><span class="highlight">Everolimus</span>. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-2018 Feb 26.</li>_x000D_ <li>Guan TW, Lin YJ, Ou MY, Chen KB. Efficacy and safety of <span class="highlight">everolimus</span> treatment on liver transplant recipients: A meta-analysis. <span role="menubar">Eur J Clin Invest.</span> 2019 Dec;49(12):e13179.</li>_x000D_ <li>Hasskarl J. Everolimus. <span class="jrnl" title="Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer">Recent Results Cancer Res</span>. 2018;211:101-123.</li>_x000D_ <li>Moes DJ, Guchelaar HJ, de Fijter JW. Sirolimus and everolimus in kidney transplantation. <span class="jrnl" title="Drug discovery today">Drug Discov Today</span>. 2015 Oct;20(10):1243-9.</li>_x000D_ <li>Vernieri C, Corti F, Nichetti F, Ligorio F, Manglaviti S, Zattarin E, Rea CG, Capri G, Bianchi GV, de Braud F. Everolimus versus alpelisib in advanced hormone receptor-positive HER2-negative breast cancer: targeting different nodes of the PI3K/AKT/mTORC1 pathway with different clinical implications. <span class="jrnl" title="Breast cancer research : BCR">Breast Cancer Res</span>. 2020 Apr 6;22(1):33.</li>_x000D_ <li>Sammons S, Sedrak MS and Kimmick GG. The Evolving Complexity of Treating Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer: Special Considerations in Older Breast Cancer Patients-Part I: Early-Stage Disease. <span class="jrnl" title="Drugs &amp; aging">Drugs Aging</span>. 2020 Feb 26.</li>_x000D_ </ul>_x000D_ <strong>Related Products</strong>_x000D_ _x000D_ https://moleculardepot.com/product/sirolimus-bsa-conjugate/_x000D_ _x000D_ https://moleculardepot.com/product/tacrolimus-bsa-conjugate-p2010001/_x000D_ _x000D_ &nbsp;